Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Latest Data on Cancer Immunotherapy’s Interaction with Autoimmunity

Thomas R. Collins  |  Issue: February 2019  |  February 18, 2019

Possible Autoimmune Effects

Two autoimmune syndromes are due to an insufficiency of CTLA-4 have been identified, and evidence indicates defective checkpoint biology contributes to the pathogenesis of rheumatoid arthritis (RA). Ex-vivo studies have shown that blockade of PD-1 leads to enhancement and pro­liferation of memory T cells in RA.2,3

Conflicting data on the function of the PD pathway in rheumatoid arthritis (RA) exist, but a recent paper looking at synovial tissue from RA patients, those with other diseases and controls found a transcriptomic signature associated with the effects of anti-PD-1 therapy.4 “The results suggest the PD-1 pathway is quite similar between active RA and cancer patients treated on anti-PD-1 therapy,” Dr. Calabrese said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Uncertainty remains about immune-related adverse events (irAEs) associated with checkpoint inhibition. Although they’ve been widely reported on, Dr. Calabrese said it’s not known whether these events represent “true autoimmune diseases—classical forms of autoimmune disease that are being expressed in this challenged population—or do they represent some form of autoimmune-like disease,” he said. Almost all reports of irAEs are based on clinical descriptions, with pathophysiological investigations rare.

We do know irAEs mostly occur within the first 13 weeks, although some can be delayed and not appear until after the drug is discontinued. They can occur alone or in combination, and most are self-limiting with treatment or stoppage of the CPI, although rheumatic irAEs can be ongoing.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Calabrese emphasized the importance of vigilance for hypophysitis, which has gone from a pre-irAE incidence of one in seven per 9 million to as high as 10–15 per 100 in certain at-risk CTLA-4 recipients.

Recent findings clearly show an overall survival advantage for those experiencing an irAE and those not, indicating an irAE might serve as a biomarker for the anti-tumor response.5

Data had suggested immunosuppressive drugs don’t dampen the likelihood of a response to a checkpoint inhibitor, but recent studies have cast doubt on that finding, including a look at data from two centers that found those on 10 mg or more of prednisone had a less likely chance of responding to a checkpoint inhibitor, after controlling for a variety of variables.6

Going forward, a multidisciplinary approach to treating these patients is needed, Dr. Calabrese said. “We need to work with our oncology colleagues, and we need early referrals,” he said. “We need systems to see these patients. They can’t wait four-and-a-half months for a rheumatology consult.” 


Thomas R. Collins is a freelance writer living in South Florida.

References

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:2018 ACR/ARHP Annual MeetingCancerCheckpoint Inhibitorsimmune-related adverse events

Related Articles
    Lightspring/shutterstock.com

    The Immune Checkpoint Inhibitors Unleashed to Fight Cancer

    May 17, 2017

    A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…

    Alpha Tauri 3D Graphics / shutterstock.com

    Rheumatic Complications from Immune Checkpoint Inhibitors

    December 16, 2021

    Immune checkpoint inhibitors (ICIs), such as anti-programmed cell-death 1/programmed death-ligand 1 (anti-PD-1/PD-L1) or anti-CTL-associated protein (anti-CTLA-4), have dramatically changed the treatment of advanced cancers over the past decade. ICIs block T cell inhibition, thus increasing the anti-tumor immune response. ICIs are used not only for metastatic cancer, but also as adjuvant treatment for some stage…

    Case Report: Tumor Treatment Unleashes Autoimmunity

    November 17, 2019

    Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) axes have revolutionized therapy and improved survival in advanced cancers. However, these immune system modulators also lead to immune-related adverse events (IRAEs).1,2 In clinical trials, IRAEs mainly involved the gastrointestinal tract, skin, endocrine glands, liver and lung,…

    Immune Checkpoint Inhibitors & Immune-Related Adverse Events

    September 20, 2018

    Immune checkpoint inhibitors (ICIs) are at the forefront of advances in cancer therapy and have shown promising results for progression-free survival. Checkpoint signaling pathways, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), normally regulate the immune response to promote self-tolerance and prevent tissue damage and inflammation. PD-1 is a…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences